• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

可待因及其代谢产物在高加索健康志愿者体内的药代动力学:异喹胍强代谢型与弱代谢型的比较。

Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine.

作者信息

Yue Q Y, Hasselström J, Svensson J O, Säwe J

机构信息

Department of Clinical Pharmacology, Huddinge University Hospital, Karolinska Institute, Sweden.

出版信息

Br J Clin Pharmacol. 1991 Jun;31(6):635-42. doi: 10.1111/j.1365-2125.1991.tb05585.x.

DOI:10.1111/j.1365-2125.1991.tb05585.x
PMID:1867957
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1368572/
Abstract
  1. The kinetics of codeine and seven of its metabolites codeine-6-glucuronide (C6G), norcodeine (NC), NC-glucuronide (NCG), morphine (M), M-3 (M3G) and 6-glucuronides (M6G), and normorphine (NM) were investigated after a single oral dose of 50 mg codeine phosphate in 14 healthy Caucasian subjects including eight extensive (EM) and six poor (PM) hydroxylators of debrisoquine. The plasma and urine concentrations of codeine and the metabolites were measured by h.p.l.c. 2. The mean area under the curve (AUC), half-life and total plasma clearance of codeine were 1020 +/- 340 nmol l-1 h, 2.58 +/- 0.57 h and 2.02 +/- 0.73 l h-1 kg-1, respectively. There were no significant differences between EM and PM in these aspects. 3. PM had significantly lower AUC of M3G, the active metabolites M6G, NM and M (P less than 0.0001), and lower partial metabolic clearance by O-demethylation (P less than 0.0001). In contrast, the PM had higher AUC of NC (P less than 0.05) than the EM. There was no difference between PM and EM in the AUC of C6G and NCG, nor in the partial clearances by N-demethylation and glucuronidation. 4. Among EM, the AUC of C6G was 15 times higher than that of codeine, which in turn was 50 times higher than that of M. The AUCs of M6G and NM were about 6 and 10 times higher than that of M, respectively. The partial clearance by glucuronidation was about 8 and 12 times higher than those by N- and O-demethylations, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)
摘要
  1. 在14名健康的白种人受试者(包括8名异喹胍代谢快型(EM)和6名异喹胍代谢慢型(PM))中,单次口服50毫克磷酸可待因后,研究了可待因及其7种代谢产物可待因-6-葡萄糖醛酸苷(C6G)、去甲可待因(NC)、去甲可待因葡萄糖醛酸苷(NCG)、吗啡(M)、吗啡-3-葡萄糖醛酸苷(M3G)、6-葡萄糖醛酸吗啡(M6G)和去甲吗啡(NM)的动力学。通过高效液相色谱法测定可待因及其代谢产物在血浆和尿液中的浓度。2. 可待因的平均曲线下面积(AUC)、半衰期和血浆总清除率分别为1020±340纳摩尔/升·小时、2.58±0.57小时和2.02±0.73升/小时·千克-1。在这些方面,EM和PM之间没有显著差异。3. PM的M3G、活性代谢产物M6G、NM和M的AUC显著较低(P<0.0001),通过O-去甲基化的部分代谢清除率也较低(P<0.0001)。相比之下,PM的NC的AUC高于EM(P<0.05)。PM和EM在C6G和NCG的AUC方面没有差异,在通过N-去甲基化和葡萄糖醛酸化的部分清除率方面也没有差异。4. 在EM中,C6G的AUC比可待因高15倍,可待因的AUC又比M高50倍。M6G和NM的AUC分别比M高约6倍和10倍。通过葡萄糖醛酸化的部分清除率分别比通过N-去甲基化和O-去甲基化的部分清除率高约8倍和12倍。(摘要截短至250字)

相似文献

1
Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine.可待因及其代谢产物在高加索健康志愿者体内的药代动力学:异喹胍强代谢型与弱代谢型的比较。
Br J Clin Pharmacol. 1991 Jun;31(6):635-42. doi: 10.1111/j.1365-2125.1991.tb05585.x.
2
Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation.可待因O-去甲基化与多态性异喹胍羟基化共分离。
Br J Clin Pharmacol. 1989 Dec;28(6):639-45. doi: 10.1111/j.1365-2125.1989.tb03556.x.
3
A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine.可待因及其代谢产物在健康中国人和白种人强异喹胍羟基化者体内的药代动力学比较。
Br J Clin Pharmacol. 1991 Jun;31(6):643-7. doi: 10.1111/j.1365-2125.1991.tb05586.x.
4
The effect of codeine on gastrointestinal transit in extensive and poor metabolisers of debrisoquine.可待因对异喹胍广泛代谢者和代谢不良者胃肠道转运的影响。
Eur J Clin Pharmacol. 1997;53(2):145-8. doi: 10.1007/s002280050353.
5
Interindividual and interethnic differences in the demethylation and glucuronidation of codeine.可待因去甲基化和葡萄糖醛酸化的个体间及种族间差异。
Br J Clin Pharmacol. 1989 Dec;28(6):629-37. doi: 10.1111/j.1365-2125.1989.tb03555.x.
6
Metabolism, pharmacokinetics and selected pharmacodynamic effects of codeine following a single oral administration to horses.犬单次口服可待因后的代谢、药代动力学和部分药效学研究
Vet Anaesth Analg. 2020 Sep;47(5):694-704. doi: 10.1016/j.vaa.2020.04.004. Epub 2020 Apr 23.
7
Post-mortem levels and tissue distribution of codeine, codeine-6-glucuronide, norcodeine, morphine and morphine glucuronides in a series of codeine-related deaths.一系列与可待因相关死亡案例中可待因、可待因 -6- 葡萄糖醛酸苷、去甲可待因、吗啡及吗啡葡萄糖醛酸苷的尸检水平和组织分布
Forensic Sci Int. 2016 May;262:128-37. doi: 10.1016/j.forsciint.2016.02.051. Epub 2016 Mar 4.
8
On the assessment of drug metabolism by assays of codeine and its main metabolites.通过可待因及其主要代谢物的测定评估药物代谢
Ther Drug Monit. 2000 Jun;22(3):258-65. doi: 10.1097/00007691-200006000-00005.
9
Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers.一名慢代谢者和七名快代谢者单次及长期服用可待因后的处置与代谢情况。
Br J Clin Pharmacol. 1991 Apr;31(4):381-90. doi: 10.1111/j.1365-2125.1991.tb05550.x.
10
Urine and plasma pharmacokinetics of codeine in healthy volunteers: implications for drugs-of-abuse testing.健康志愿者中可待因的尿液和血浆药代动力学:对药物滥用检测的意义。
J Anal Toxicol. 1996 Nov-Dec;20(7):541-6. doi: 10.1093/jat/20.7.541.

引用本文的文献

1
Physiologically based pharmacokinetic modeling to predict the pharmacokinetics of codeine in different CYP2D6 phenotypes.基于生理的药代动力学建模以预测不同CYP2D6表型中可待因的药代动力学。
Front Pharmacol. 2024 May 2;15:1342515. doi: 10.3389/fphar.2024.1342515. eCollection 2024.
2
Hydrocodone, Oxycodone, and Morphine Metabolism and Drug-Drug Interactions.氢可酮、羟考酮和吗啡的代谢与药物相互作用。
J Pharmacol Exp Ther. 2023 Nov;387(2):150-169. doi: 10.1124/jpet.123.001651. Epub 2023 Sep 7.
3
Non-Peptide Opioids Differ in Effects on Mu-Opioid (MOP) and Serotonin 1A (5-HT) Receptors Heterodimerization and Cellular Effectors (Ca, ERK1/2 and p38) Activation.非肽类阿片样物质对μ-阿片受体(MOP)和血清素 1A 受体(5-HT)异源二聚体及细胞效应器(Ca、ERK1/2 和 p38)激活的影响存在差异。
Molecules. 2022 Apr 6;27(7):2350. doi: 10.3390/molecules27072350.
4
Application of Model Informed Precision Dosing to Address the Impact of Pregnancy Stage and CYP2D6 Phenotype on Foetal Morphine Exposure.应用模型指导下的精准剂量调整以解决妊娠阶段和 CYP2D6 表型对胎儿吗啡暴露的影响。
AAPS J. 2021 Jan 6;23(1):15. doi: 10.1208/s12248-020-00541-1.
5
Update of the Scientific Opinion on opium alkaloids in poppy seeds.罂粟籽中鸦片生物碱的科学意见更新。
EFSA J. 2018 May 16;16(5):e05243. doi: 10.2903/j.efsa.2018.5243. eCollection 2018 May.
6
The Ontogeny of UDP-glucuronosyltransferase Enzymes, Recommendations for Future Profiling Studies and Application Through Physiologically Based Pharmacokinetic Modelling.UDP-葡糖醛酸基转移酶酶的个体发生,未来分析研究的建议及通过生理基于药代动力学建模的应用。
Clin Pharmacokinet. 2019 Feb;58(2):189-211. doi: 10.1007/s40262-018-0681-2.
7
Guidance on opioids prescribing for the management of persistent non-cancer pain in older adults.老年人持续性非癌性疼痛管理中阿片类药物处方指南。
World J Clin Cases. 2017 Mar 16;5(3):73-81. doi: 10.12998/wjcc.v5.i3.73.
8
[Personalized drug therapy based on genetics. Possibilities and examples from clinical practice].[基于遗传学的个性化药物治疗。临床实践中的可能性与实例]
Internist (Berl). 2016 Mar;57(3):289-97. doi: 10.1007/s00108-015-0013-7.
9
Cross-reactivity of the CEDIA buprenorphine assay in drugs-of-abuse screening: influence of dose and metabolites of opioids.CEDIA丁丙诺啡检测法在药物滥用筛查中的交叉反应性:阿片类药物剂量及代谢物的影响
Subst Abuse Rehabil. 2015 Oct 28;6:131-9. doi: 10.2147/SAR.S88935. eCollection 2015.
10
Opioid and chronic non-cancer pain.阿片类药物与慢性非癌性疼痛
J Anaesthesiol Clin Pharmacol. 2013 Jan;29(1):6-12. doi: 10.4103/0970-9185.105784.

本文引用的文献

1
Analgesic potency of normorphine in patients with postoperative pain.
J Pharmacol Exp Ther. 1958 Nov;124(3):260-3.
2
The effect of N-demethylation on certain pharmacologic actions of morphine, codeine, and meperidine in the mouse.N-去甲基化对小鼠体内吗啡、可待因和哌替啶某些药理作用的影响。
J Pharmacol Exp Ther. 1954 Oct;112(2):191-6.
3
A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.对英国白人人群中异喹胍氧化遗传多态性的家系及群体研究。
J Med Genet. 1980 Apr;17(2):102-5. doi: 10.1136/jmg.17.2.102.
4
Patient-controlled analgesic therapy, Part IV: pharmacokinetics and analgesic plasma concentrations of morphine.
Clin Pharmacokinet. 1982 May-Jun;7(3):266-79. doi: 10.2165/00003088-198207030-00006.
5
Analgesic effect of morphine glucuronides.吗啡葡萄糖醛酸苷的镇痛作用。
Tohoku J Exp Med. 1971 Sep;105(1):45-52. doi: 10.1620/tjem.105.45.
6
Biochemical basis for analgesic activity of morphine-6-glucuronide. I. Penetration of morphine-6-glucuronide in the brain of rats.吗啡 -6-葡萄糖醛酸苷镇痛活性的生化基础。I. 吗啡 -6-葡萄糖醛酸苷在大鼠脑中的渗透。
Biochem Pharmacol. 1973 Jun 15;22(12):1423-30. doi: 10.1016/0006-2952(73)90320-1.
7
Oral morphine in cancer patients: in vivo kinetics and in vitro hepatic glucuronidation.癌症患者口服吗啡:体内动力学与体外肝脏葡萄糖醛酸化
Br J Clin Pharmacol. 1985 Apr;19(4):495-501. doi: 10.1111/j.1365-2125.1985.tb02675.x.
8
Plasma concentrations of codeine and its metabolite, morphine, after single and repeated oral administration.
Eur J Clin Pharmacol. 1986;30(6):673-7. doi: 10.1007/BF00608214.
9
High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment.癌症患者的大剂量吗啡和美沙酮。口服治疗的临床药代动力学考量
Clin Pharmacokinet. 1986 Mar-Apr;11(2):87-106. doi: 10.2165/00003088-198611020-00001.
10
Oral administration of codeine in the presence of ethanol: a pharmacokinetic study in man.乙醇存在时口服可待因:人体药代动力学研究
Pharmacol Toxicol. 1987 Nov;61(5):297-300. doi: 10.1111/j.1600-0773.1987.tb01822.x.